Description

Pyrazolo[3,4-B]Azepine, 3-(2-Benzofuranyl)-1-(3-Bromophenyl)-1,4,5,6,7,8-Hexahydro- (9Ci) is a complex heterocyclic organic compound featuring a fused pyrazole and azepine core structure, substituted with benzofuranyl and bromophenyl groups. This molecular architecture makes it a valuable and versatile advanced pharmaceutical intermediate for research and development. It is primarily sought by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the synthesis of novel bioactive molecules.

Application

This specialized intermediate is designed for high-value synthetic applications, particularly in medicinal chemistry and advanced material science.

• Pharmaceutical Intermediate: Key building block for the research and synthesis of new drug candidates targeting central nervous system (CNS) disorders, oncology, and inflammation.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies and library synthesis for high-throughput screening due to its privileged scaffold.
• Organic Synthesis Reference Standard: Serves as a pure standard for analytical method development and validation in QC laboratories.
• Biochemical Tool Compound: Potential use in probing biological pathways and enzyme interactions in academic and industrial research settings.
• Fine Chemical Synthesis: Intermediate for creating more complex, functionalized heterocyclic compounds for specialized applications.

Basic Information

Product Name	Pyrazolo[3,4-B]Azepine, 3-(2-Benzofuranyl)-1-(3-Bromophenyl)-1,4,5,6,7,8-Hexahydro- (9Ci)
CAS No.	581773-79-7
Molecular Formula	C23H21BrN2O
Molecular Weight	421.33 g/mol
Synonyms	3-(Benzofuran-2-yl)-1-(3-bromophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-b]azepine; 1-(3-Bromophenyl)-3-(2-benzofuranyl)-4,5,6,7,8-hexahydro-1H-pyrazolo[3,4-b]azepine; 3-(2-Benzofuranyl)-1-(3-bromophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-b]azepine; Pyrazolo[3,4-b]azepine, 3-(2-benzofuranyl)-1-(3-bromophenyl)-1,4,5,6,7,8-hexahydro-; 581773-79-7; 1-(3-Bromophenyl)-3-(1-benzofuran-2-yl)-4,5,6,7,8-hexahydro-1H-pyrazolo[3,4-b]azepine
EINECS	Contact for details

Quality Control

Our production of this high-purity intermediate adheres to strict quality management systems. Every batch undergoes comprehensive analytical characterization to ensure identity, purity, and consistency. Certificates of Analysis (COA) detailing specifications such as HPLC purity, NMR confirmation, and residual solvent levels are provided and available upon request. We support cGMP-compliant documentation for advanced pharmaceutical applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The compound may be light-sensitive and should be handled under an inert atmosphere for long-term stability. Keep container tightly sealed in a dry environment to minimize moisture uptake.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 97.0%
Loss on Drying	≤ 0.5%
Residual Solvents (GC)	Meets ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.